Proxy Votes Now

Home › Funds › Fidelity › Select Health Care Portfolio

Select Health Care Portfolio (FHCLX) proxy voting record 2025-2026

Fund family: Fidelity · Filed by FIDELITY SELECT PORTFOLIOS (CIK 320351) · SEC series S000007466

Share classes and tickers: FHCLX (C000272243), FHCNX (C000272244), FHCPX (C000272245), FHCQX (C000272241), FHCRX (C000272242), FSPHX (C000020440)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 757 with, 15 against, 0 abstentions (not counted as with management). Shareholder proposals: 0 FOR, 15 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Fidelity as a whole

The same two figures as Fidelity’s manager page (1,165,189 ballot items across 406 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsFidelityItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)93.6%71994.1%974,562
Backed environmental and social shareholder proposals at US companiesn/a66.8%11,096

Where this fund voted differently from most Fidelity funds

Each ballot item this fund voted is set against the votes of the other Fidelity funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most Fidelity funds on 14 items (1.9% of the 745 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost Fidelity fundsMgmtResult
Summit Therapeutics Inc.2026-06-10ELECTION OF DIRECTORS: Kenneth A. ClarkWithholdFOR — 15 of 21 Fidelity fundsAgainstPassed (calculated), 96.1% support
Summit Therapeutics Inc.2026-06-10ELECTION OF DIRECTORS: Mahkam ZanganehWithholdFOR — 15 of 21 Fidelity fundsAgainstPassed (calculated), 98.5% support
Summit Therapeutics Inc.2026-06-10ELECTION OF DIRECTORS: Manmeet S. SoniWithholdFOR — 15 of 21 Fidelity fundsAgainstPassed (calculated), 98.4% support
Summit Therapeutics Inc.2026-06-10ELECTION OF DIRECTORS: Robert W. DugganWithholdFOR — 15 of 21 Fidelity fundsAgainstPassed (calculated), 98.3% support
Summit Therapeutics Inc.2026-06-10ELECTION OF DIRECTORS: Yu (Michelle) XiaWithholdFOR — 15 of 21 Fidelity fundsAgainstPassed (calculated), 98.3% support
Summit Therapeutics Inc.2026-06-10Approval, by a non-binding advisory vote, of the compensation of our named executive officers.ForAGAINST — 17 of 25 Fidelity fundsForPassed (calculated), 96.2% support
Rezolute, Inc.2025-11-19To elect the seven nominees to the Company's Board of Directors to serve until the 2027 Annual Meeting of Stockholders, until his or her successor is elected and shall have qualified or until his or her death, resignation, removal or disqualification: Erik HarrisWithholdFOR — 12 of 17 Fidelity fundsAgainstPassed (calculated), 81.2% support
Rezolute, Inc.2025-11-19To elect the seven nominees to the Company's Board of Directors to serve until the 2027 Annual Meeting of Stockholders, until his or her successor is elected and shall have qualified or until his or her death, resignation, removal or disqualification: Nerissa KreherWithholdFOR — 12 of 17 Fidelity fundsAgainstPassed (calculated), 76.6% support
Galecto, Inc.2026-02-09Approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of the Common Stock from 300,000,000 to 500,000,000.AgainstFOR — 3 of 3 Fidelity fundsAgainst—
Galecto, Inc.2026-02-09Approve the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposal Nos. 1, 2, 3, 4 and/or 5.AgainstFOR — 3 of 3 Fidelity fundsAgainst—
Stoke Therapeutics, Inc.2026-06-03Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Julie Anne SmithWithholdFOR — 14 of 25 Fidelity fundsAgainstPassed (calculated), 86.9% support
Stoke Therapeutics, Inc.2026-06-03Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Adrian Krainer, Ph.D.WithholdFOR — 13 of 25 Fidelity fundsAgainstPassed (calculated), 73.0% support
Sartorius Stedim Biotech SA2026-03-24Approve Compensation Report of Corporate OfficersForAGAINST — 7 of 12 Fidelity fundsFor—
Sartorius Stedim Biotech SA2026-03-24Approve Remuneration Policy of CEOForAGAINST — 7 of 12 Fidelity fundsFor—

Download all 14 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 84.7% of this fund’s 772 such votes could be given a sector; the other 118 (15.3%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care585142.4%
Industrials3700.0%
Consumer Staples1715.9%
Technology1500.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections4550
Audit-related1070
Say-on-Pay880
Compensation470
Corporate Governance449
Capital Structure320
Extraordinary Transactions40
Other Social Issues43
Environment or Climate33
Shareholder Rights and Defenses20

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Eli Lilly and CompanyMay 4, 2026$585M102
Danaher CorporationMay 5, 2026$435M140
Johnson & JohnsonApril 23, 2026$385M151
AbbVie Inc.May 8, 2026$318M81
Moderna, Inc.May 6, 2026$314M50
argenx SENovember 18, 2025$266M10
Boston Scientific CorporationApril 30, 2026$214M171
Gilead Sciences, Inc.April 30, 2026$181M153

Notable votes against management

MeetingCompanyProposalFundMgmt
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalAgainstFor
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
April 23, 2026Johnson & JohnsonIndependent Board Chair Shareholder proposalAgainstFor
May 8, 2026AbbVie Inc.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalAgainstFor
April 30, 2026Boston Scientific CorporationStockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting." Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
June 1, 2026UnitedHealth Group IncorporatedIf properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposalAgainstFor
May 14, 2026CVS Health CorporationStockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposalAgainstFor
April 22, 2026The Cigna GroupShareholder Proposal - Shareholder Right to Act by Written Consent Shareholder proposalAgainstFor

Funds that vote the same way

These funds reported the same votes as Select Health Care Portfolio in the latest season (or all but a few items), so they share this page:

Search this fund’s votes by company

786 ballot items at 100 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Select Health Care Portfolio (FHCLX) voted at 100 shareholder meetings of 98 companies, on 786 ballot items in all. Where management made a recommendation, the fund followed it on 98.1% of the items and voted against it 15 times. Its most frequent area of disagreement was corporate governance (9 of its votes against management). It voted on 15 shareholder proposals. It voted FOR the board's own proposals less often than Fidelity's funds as a whole (93.6% against 94.1%). It voted differently from most Fidelity funds on 14 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Fidelity’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.